about
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.Changes in practice and perception of hepatitis C and liver transplantation: Results of a national surveyNetwork-based recruitment of people who inject drugs for hepatitis C testing and linkage to careHepatitis C-positive donor liver transplantation for hepatitis C seronegative recipientsPatient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single SiteHepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV ContinuumNurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trialUnreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugsImpact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence
P50
Q45325188-78870AA6-D13E-4754-A0D8-73578492FD33Q47274505-6C88E8E2-61D8-4BD3-96E0-01144C139C20Q47560922-FBC73FC7-D5A8-4BB1-AF63-39CA79CD4603Q58423262-EBC84F3E-9FFB-4067-92DE-EBD47819352AQ89653952-2D878BBE-9AB3-47D0-ACF8-50E2615F382FQ90690615-C819E257-D7D5-4B35-BB1F-13E9E58269E0Q90743981-C0F11F47-74D3-4B7E-BEBF-D3E4F1A29E18Q91016290-50482FFC-FCDD-4C78-8D9E-C87B154C11C6Q91370921-A8F7D47C-EE4E-4DB3-8EA9-5ECD50721BEEQ92107485-A717B8B9-F5FD-4A70-B71E-6F5FEEF4629CQ94467162-25FDD6BB-9C97-4EE4-8C4B-C149EEFF4DF8
P50
description
researcher
@en
wetenschapper
@nl
name
Mark Sulkowski
@en
Mark Sulkowski
@nl
type
label
Mark Sulkowski
@en
Mark Sulkowski
@nl
prefLabel
Mark Sulkowski
@en
Mark Sulkowski
@nl
P31
P496
0000-0002-2145-6352